WO2022052822A1 - Resmetirom的晶型及其制备方法和用途 - Google Patents

Resmetirom的晶型及其制备方法和用途 Download PDF

Info

Publication number
WO2022052822A1
WO2022052822A1 PCT/CN2021/115205 CN2021115205W WO2022052822A1 WO 2022052822 A1 WO2022052822 A1 WO 2022052822A1 CN 2021115205 W CN2021115205 W CN 2021115205W WO 2022052822 A1 WO2022052822 A1 WO 2022052822A1
Authority
WO
WIPO (PCT)
Prior art keywords
csvi
crystal form
preparation
crystal
compound
Prior art date
Application number
PCT/CN2021/115205
Other languages
English (en)
French (fr)
Inventor
陈敏华
黄春香
Original Assignee
苏州科睿思制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州科睿思制药有限公司 filed Critical 苏州科睿思制药有限公司
Priority to EP21865878.9A priority Critical patent/EP4286377A1/en
Priority to CN202180055080.9A priority patent/CN116171275A/zh
Priority to JP2023515709A priority patent/JP2023541870A/ja
Priority to US18/044,717 priority patent/US20230416234A1/en
Priority to KR1020237011972A priority patent/KR20230066408A/ko
Priority to AU2021341182A priority patent/AU2021341182A1/en
Priority to CA3192243A priority patent/CA3192243A1/en
Publication of WO2022052822A1 publication Critical patent/WO2022052822A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to the field of crystal chemistry. Specifically, it relates to the crystal form of Resmetirom and its preparation method and use.
  • Heterozygous familial hypercholesterolemia is the most severe form of lipid metabolism disorders and can lead to various life-threatening complications of cardiovascular disease.
  • Nonalcoholic steatohepatitis is a severe liver disease with steatosis accompanied by inflammation and liver cell damage.
  • Resmetirom a thyroid hormone receptor THR- ⁇ selective agonist, can improve the symptoms of NASH and HeFH by reducing LDL cholesterol, triglyceride, and hepatic fat levels and stimulating hepatic mitochondrial biosynthesis in individuals with NASH. Resmetirom has achieved positive results in Phase II clinical trials in NASH and HeFH.
  • a crystal is a solid in which the molecules of a compound are arranged in a three-dimensional order in a microstructure to form a crystal lattice.
  • Polymorphism is the phenomenon in which a compound exists in more than one crystal form.
  • Compounds may exist in one or more crystalline forms, but their existence and identity cannot be specifically expected.
  • APIs with different crystal forms have different physicochemical properties, which may lead to different dissolution and absorption of the drug in the body, thereby affecting the clinical efficacy of the drug to a certain extent.
  • the crystal form is very important to the product performance.
  • the physicochemical properties of the crystal form are crucial to the production process.
  • US9266861B2 discloses compound I hydrate, anhydrous form I, methyl isobutyl ketone solvate, dimethylacetamide solvate. According to the ICH regulations on the classification of residual solvents, methyl isobutyl ketone and dimethylacetamide are both class II solvents, which are severely toxic with restricted use, and are not suitable for medicinal use. US9266861B2 discloses that the hydrate purity of compound I is only 96.4% (HPLC), and its high impurity content will cause variation in the appearance of the drug, affect the stability of the drug, and increase toxic and side effects.
  • WO2020010068A1 discloses various salt form crystal forms of compound I, such as calcium salt, magnesium salt, sodium salt, potassium salt, ethanolamine salt, etc. At the same time, it discloses 27 free crystal forms of Compound I, including a variety of solvate crystal forms (such as methanol solvate, acetone solvate, tetrahydrofuran solvate, methyl isobutyl ketone solvate, acetonitrile solvate) solvate, dimethyl sulfoxide solvate, dimethylacetamide solvate) and multiple desolvated crystalline forms.
  • solvate crystal forms such as methanol solvate, acetone solvate, tetrahydrofuran solvate, methyl isobutyl ketone solvate, acetonitrile solvate
  • the crystal form A and the crystal form I disclosed in US9266861B2 are the same crystal form, the desolvate crystal form F has high hygroscopicity, and the desolvate crystal form S +T, crystal form V, crystal form W, and crystal form Z are all mixed crystals composed of non-single crystal forms.
  • Form I is a known solid form of compound I with relatively good properties, but form I needs to be prepared from specific starting materials, such as methyl isobutyl ketone solvate, dimethylacetamide solvate.
  • the inventor of the present application repeated the preparation method disclosed in US9266861B2 to obtain crystal form I, and characterized the properties of crystal form I.
  • the results show that crystal form I has low solubility and poor grinding stability. , the liquidity is very poor. Therefore, there is still a need in the art to develop a single crystalline form of Compound I with high solubility, good physicochemical stability, safety and non-toxicity, and good physicochemical properties, for the development of drugs containing Compound I.
  • the inventors of the present application have conducted a large number of experimental studies on Compound I in an attempt to obtain a crystal form that is more suitable for medicinal use. They have conducted more than 300 experiments, but most of the obtained compounds are Compound I solvates, such as methanol solvate and acetone solvent. solvate, tetrahydrofuran solvate, chlorobenzene solvate, toluene solvate, cyclohexanone solvate, etc.
  • the inventors of the present application found that Compound I is very easy to combine with a solvent to form a solvate, and it is very difficult to obtain a stable single crystal form of an unsolvate.
  • the inventors of the present application have unexpectedly discovered the compound I crystal form CSVI provided by the present invention, which has the advantages of solubility, hygroscopicity, purification effect, stability, adhesion, compressibility, fluidity, in vitro and in vivo dissolution, bioavailability, etc. At least one of them has advantages, especially high solubility, good physical and chemical stability, good mechanical stability, low hygroscopicity, good fluidity, good compressibility, low adhesion, and good formulation stability, which solve the existing problems.
  • the technical problems are of great significance to the development of drugs containing compound I.
  • the present invention provides a new crystal form of compound I, a preparation method thereof, and a pharmaceutical composition comprising the new crystal form.
  • the present invention provides the crystal form CSVI of compound I (hereinafter referred to as "crystal form CSVI").
  • the X-ray powder diffraction pattern of the crystalline form CSVI has characteristic peaks at diffraction angle 2 ⁇ values of 9.6° ⁇ 0.2°, 10.1° ⁇ 0.2°, and 18.9° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form CSVI has a diffraction angle 2 ⁇ value of 11.6° ⁇ 0.2°, 19.5° ⁇ 0.2°, 23.3° ⁇ 0.2°, or 2
  • a diffraction angle 2 ⁇ value 11.6° ⁇ 0.2°, 19.5° ⁇ 0.2°, 23.3° ⁇ 0.2°, or 2
  • characteristic peaks at or at 3 places preferably, the X-ray powder diffraction pattern of the crystalline form CSVI has 3 places in the diffraction angle 2 ⁇ of 11.6° ⁇ 0.2°, 19.5° ⁇ 0.2°, and 23.3° ⁇ 0.2°. Characteristic peaks.
  • the X-ray powder diffraction pattern of the crystal form CSVI has a diffraction angle 2 ⁇ value of 13.7° ⁇ 0.2°, 20.6° ⁇ 0.2°, 31.9° ⁇ 0.2°, or 2
  • a diffraction angle 2 ⁇ value 13.7° ⁇ 0.2°, 20.6° ⁇ 0.2°, 31.9° ⁇ 0.2°, or 2
  • characteristic peaks at or at 3 places preferably, the X-ray powder diffraction pattern of the crystalline form CSVI has 3 places in the diffraction angle 2 ⁇ of 13.7° ⁇ 0.2°, 20.6° ⁇ 0.2°, and 31.9° ⁇ 0.2°. Characteristic peaks.
  • the X-ray powder diffraction pattern of the crystalline form CSVI has diffraction angle 2 ⁇ values of 9.6° ⁇ 0.2°, 10.1° ⁇ 0.2°, 11.6° ⁇ 0.2°, 18.9° ⁇ 0.2° , 19.5° ⁇ 0.2°, 23.3° ⁇ 0.2°, 13.7° ⁇ 0.2°, 20.6° ⁇ 0.2°, 31.9° ⁇ 0.2°, 6.5° ⁇ 0.2°, 16.2° ⁇ 0.2°, 21.9° ⁇ 0.2°, 24.1
  • the X-ray powder diffraction pattern of the crystalline form CSVI is substantially as shown in FIG. 1 .
  • thermogravimetric analysis diagram of the crystalline form CSVI is substantially as shown in Figure 2, which has a mass loss of about 0.2% when heated to 250°C.
  • the crystalline form CSVI has a hygroscopic weight gain of 0.07% under the condition of 25° C./80% RH, which has no or almost no hygroscopicity, and its DVS diagram is basically shown in FIG. 3 .
  • the crystalline form CSVI is an anhydrous form.
  • the present invention also provides a preparation method of crystal form CSVI, characterized in that the preparation method comprises:
  • the nitriles described in the method (1) are preferably acetonitrile, and the volume ratio of acetonitrile and water in the mixed solvent is preferably 95:5; the nitriles described in the method (2) are preferably acetonitrile, the alcohols are preferably isopropanol, and the mixed solvent
  • the volume ratio of acetonitrile and water is preferably 95:5, and the volume ratio of acetonitrile and isopropanol is preferably 1:1.
  • the stirring temperature of the method (1) is preferably -20°C-76°C, more preferably -20°C-30°C; the drying temperature is preferably 10°C-70°C, more preferably 10°C-40°C.
  • the dissolution temperature of the method (2) is preferably 40°C-76°C; the cooling temperature is preferably -20°C-5°C, more preferably -20°C; the drying temperature is preferably 10°C-70°C, more preferably 10°C-40°C.
  • the crystal form CSVI of the present invention is used to prepare other crystal forms or salts of compound I.
  • the present invention also provides a pharmaceutical composition comprising an effective therapeutic amount of the crystal form CSVI and pharmaceutically acceptable excipients.
  • the crystal form CSVI provided by the present invention has higher solubility.
  • the solubility of Form CSVI is about twice that of Form I of the prior art.
  • Compound I is a poorly water-soluble drug.
  • the crystal form CSVI provided by the present invention has higher solubility, which is beneficial to improve the absorption of the drug in the human body and improve the bioavailability; in addition, the higher solubility can reduce the dosage of the drug while ensuring the curative effect of the drug, thereby reducing the amount of the drug side effects and improve the safety of medicines.
  • the crystalline form CSVI provided by the present invention has lower hygroscopicity.
  • the test results show that the moisture-inducing weight gain of the prior art crystal form I is about 2 times that of the present invention's crystal form CSVI.
  • high hygroscopicity can easily cause chemical degradation and crystal transformation of the API, which directly affects the physicochemical stability of the API.
  • high hygroscopicity will reduce the fluidity of the API, thereby affecting the processing technology of the API.
  • drugs with high hygroscopicity need to maintain low humidity during production and storage, which puts forward higher requirements for production and requires high costs. More importantly, the high hygroscopicity can easily cause changes in the content of active ingredients in the drug, affecting the quality of the drug.
  • the crystal form CSVI provided by the present invention has better compressibility.
  • the good compressibility of the crystal form CSVI can effectively improve the unqualified hardness/brittleness, splits and other problems in the tableting process, make the formulation process more reliable, improve product appearance, and improve product quality and production efficiency.
  • the crystalline form CSVI provided by the present invention has lower adhesion.
  • the adhesion evaluation results show that the adhesion amount of the prior art crystal form I is 5 times that of the crystal form CSVI.
  • Better adhesion performance can effectively reduce the agglomeration of raw materials, can effectively improve or avoid the phenomenon of sticking wheel, sticking and punching caused by dry granulation and tablet pressing, etc. Mixing uniformity during mixing, ultimately improving product quality.
  • the crystalline form CSVI bulk drug and preparation provided by the present invention have good physical and chemical stability.
  • the bulk drug of crystal form CSVI is placed open and closed at 25°C/60% RH, the crystal form has not changed for at least 6 months, and the chemical purity is above 99.7%, and the purity remains basically unchanged during storage.
  • the crystal form CSVI is mixed with excipients to make a pharmaceutical preparation, and placed under the conditions of 25°C/60% RH, the crystal form has not changed for at least 3 months, and the purity remains basically unchanged during the storage process. It shows that the crystalline form CSVI API and preparation have good stability under long-term conditions, which is beneficial to the storage of the drug.
  • the crystal form of CSVI API was placed open and closed at 40°C/75% RH, the crystal form did not change for at least 6 months, and the chemical purity was above 99.7%, and the purity remained basically unchanged during storage.
  • the crystal form CSVI is mixed with excipients to make a pharmaceutical preparation, and placed under the condition of 40°C/75% RH, the crystal form does not change for at least 3 months, and the purity basically remains unchanged during the storage process.
  • the crystalline form CSVI API and preparation have better stability under accelerated conditions.
  • the stability of drug substances and drug products under accelerated conditions is critical for pharmaceuticals. High temperature and high humidity conditions caused by seasonal differences, climate differences in different regions and environmental factors will affect the storage, transportation and production of APIs. Therefore, the stability of the drug substance under accelerated conditions is critical for the drug.
  • the crystalline form of CSVI APIs and preparations have better stability under harsh conditions, which is beneficial to avoid the influence on the quality of the drug due to crystal transformation or decrease in purity during drug storage.
  • the crystal form CSVI provided by the present invention has good mechanical stability.
  • the crystal form of CSVI API did not change after grinding. In the process of preparation processing, it is often necessary to grind and pulverize the API, and good physical stability can reduce the risk of lowering the crystallinity of the API and the risk of crystal transformation during the preparation process. Under different pressures, the crystalline form CSVI API has good physical stability, which is conducive to maintaining the crystal form stability in the preparation and tableting process.
  • Crystal form CSVI has good physical and chemical stability, ensuring consistent and controllable quality of raw materials and preparations, reducing drug quality changes, bioavailability changes, and toxic and side effects caused by crystal form changes or impurities.
  • FIG. 4 XRPD comparison diagram of the crystal form CSVI obtained in Example 1 before and after DVS (from top to bottom: before DVS, after DVS)
  • Figure 6 XRPD comparison diagram of crystal form CSVI before and after placement under different conditions (from top to bottom: before placement, placed at 25°C/60%RH for 6 months, and 40°C/75RH for 6 months)
  • Figure 7 XRPD comparison diagram of crystal form CSVI before and after storage under different conditions (from top to bottom: before storage, placed in closed mouth at 25°C/60%RH for 6 months, and placed in closed mouth at 40°C/75RH for 6 months)
  • Figure 8 XRPD comparison chart of crystal form CSVI under different pressure conditions (from top to bottom: 14KN, 7KN, 3KN, before tableting)
  • the X-ray powder diffraction pattern of the present invention was collected on a Bruker D2 PHASER X-ray powder diffractometer.
  • the method parameters of X-ray powder diffraction of the present invention are as follows:
  • thermogravimetric analysis (TGA) plots described in the present invention were collected on a TA Q500.
  • the method parameters of thermogravimetric analysis (TGA) of the present invention are as follows:
  • the dynamic moisture adsorption (DVS) map of the present invention is collected on the Intrinsic dynamic moisture adsorption instrument produced by SMS company (Surface Measurement Systems Ltd.).
  • the instrument control software is DVS-Intrinsic control software.
  • the method parameters of the described dynamic moisture adsorption instrument are as follows:
  • Relative humidity range 0%RH-95%RH
  • Hydrogen nuclear magnetic resonance data ( 1 H NMR) were obtained from a Bruker Avance II DMX 400M HZ nuclear magnetic resonance spectrometer. Weigh 1-5 mg of the sample, dissolve it with 0.5 mL of deuterated dimethyl sulfoxide, and prepare a solution of 2-10 mg/mL.
  • test parameters of the related substance detection of the present invention are shown in Table 1:
  • test parameters of the solubility of the present invention are shown in Table 2:
  • the "stirring" is accomplished by conventional methods in the art, such as magnetic stirring or mechanical stirring, and the stirring speed is 50-1800 rev/min, wherein the magnetic stirring speed is preferably 300-900 rev/min, and the mechanical stirring The speed is preferably 100-300 revolutions per minute.
  • the “separation” is accomplished by conventional methods in the art, such as centrifugation or filtration.
  • the operation of "centrifugation” is: put the sample to be separated into a centrifuge tube, and centrifuge at a speed of 10,000 rpm until all the solids sink to the bottom of the centrifuge tube.
  • the "drying” is accomplished by conventional methods in the art, such as vacuum drying, blast drying or natural air drying.
  • the drying temperature may be room temperature or higher, preferably room temperature to about 80°C, or to 60°C, or to 40°C. Drying time can be 2-48 hours, or overnight. Drying takes place in a fume hood, blast oven or vacuum oven.
  • the “characteristic peak” refers to a representative diffraction peak used to identify crystals.
  • the peak position can usually have an error of ⁇ 0.2°.
  • crystal or “crystal form” can be characterized by X-ray powder diffraction.
  • X-ray powder diffraction pattern will vary depending on the conditions of the instrument, the preparation of the sample, and the purity of the sample.
  • the relative intensities of the diffraction peaks in the X-ray powder diffraction pattern may also vary with the experimental conditions, so the intensity of the diffraction peaks cannot be used as the only or decisive factor for determining the crystal form.
  • the relative intensities of the diffraction peaks in the X-ray powder diffraction pattern are related to the preferred orientation of the crystals, and the diffraction peak intensities shown in the present invention are illustrative and not for absolute comparison. Therefore, those skilled in the art can understand that the X-ray powder diffraction pattern of the crystal form protected by the present invention does not have to be completely consistent with the X-ray powder diffraction pattern in the embodiments referred to here, and any X-ray powder diffraction pattern with the characteristic peaks in these patterns Crystal forms with the same or similar X-ray powder diffraction patterns all fall within the scope of the present invention. Those skilled in the art can compare the X-ray powder diffraction pattern listed in the present invention with an X-ray powder diffraction pattern of an unknown crystal form to confirm whether the two sets of images reflect the same or different crystal forms.
  • the crystalline form CSVI of the present invention is pure, substantially free from admixture with any other crystalline forms.
  • substantially free when used to refer to a new crystal form means that the crystal form contains less than 20% by weight of other crystal forms, especially less than 10% by weight of other crystal forms, and even less More than 5% (weight) of other crystal forms, more refers to less than 1% (weight) of other crystal forms.
  • room temperature is not a specific temperature value, but refers to a temperature range of 10-30°C.
  • the compound I and/or its salts as raw materials include, but are not limited to, solid form (crystalline or amorphous), oily, liquid form and solution.
  • the compound I and/or its salts as starting materials are in solid form.
  • Compound I and/or its salts used in the following examples can be solid/crystalline forms disclosed in the prior art, for example, prepared according to the method described in WO2020010068A1 patent.
  • the TGA of the crystalline form CSVI is shown in Figure 2, with a mass loss of about 0.2% when heated to 250°C.
  • the DVS diagram of the crystalline form CSVI is shown in Figure 3, and its weight gain is 0.07% under the condition of 25°C/80%RH, which belongs to no or almost no hygroscopicity.
  • the XRPD pattern of the crystalline form CSVI is shown in FIG. 5 , and the XRPD data is shown in Table 4.
  • Embodiment 3 Solubility of crystal form CSVI and prior art crystal form I
  • SGF simulated gastric juice
  • the crystal form CSVI of the present invention is shown in FIG. 3 in DVS, and the XRPD diagrams before and after the DVS test are shown in FIG. 4 .
  • the experimental results show that the hygroscopic weight gain of the crystal form CSVI is 0.07% under the condition of 25°C/80%RH, and the hygroscopic weight gain of the crystal form I is 0.13% under the condition of 25°C/80%RH.
  • the moisture-inducing weight gain of the crystal form I of the prior art is about twice that of the crystal form CSVI of the present application.
  • Placement conditions put time Crystal form purity start —— CSVI 99.73% 25°C/60%RH opening 6 months CSVI 99.73% 40°C/75%RH opening 6 months CSVI 99.73% 25°C/60%RH closed 6 months CSVI 99.74% 40°C/75%RH closed 6 months CSVI 99.73%
  • the ENERPAC manual tablet press was used for tableting, ⁇ 6mm circular flat punch was selected, about 20 mg of crystal form CSVI was added, and the tablets were compressed under different pressures.
  • XRPD tests were performed before and after tableting. The test results are shown in Table 7. The XRPD patterns before and after tableting are shown in Figure 8.
  • Compressibility coefficient (%) fluidity ⁇ 10 excellent 11-15 Okay 16-20 generally 21-25 acceptable 26-31 Difference 32-37 very poor >38 very poor
  • the ENERPAC manual tablet press was used for tablet compression.
  • a ⁇ 6mm circular flat punch was selected, and 80 mg of prior art crystal form I and crystal form CSVI of the present invention were respectively added, and compressed into circular tablets with a pressure of 10 kN, and placed at room temperature.
  • the diameter (D) and thickness (L) of the tablet were measured with a vernier caliper, and its radial crushing force (hardness, H) was measured with a tablet hardness tester.
  • the formulation prescription and formulation process of crystal form CSVI are shown in Table 11 and Table 12, respectively.
  • the XRPD patterns before and after the preparation of crystal form CSVI are shown in FIG. 9 .
  • the results showed that the crystal form of CSVI remained unchanged before and after the preparation.
  • the crystalline form CSVI preparation was packaged in an HDPE bottle and added with 1 g of desiccant, placed under the conditions of 25°C/60% RH and 40°C/75% RH and sampled to detect the crystalline form and impurities, and to investigate the formulation stability of the crystalline form CSVI, The results are shown in Table 13. Before and after placing, the XRPD pattern of the preparation of the crystalline form CSVI is shown in FIG. 10 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

涉及Resmetirom（称为"化合物I"）的新晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备THR-β选择性激动剂药物和治疗NASH和HeFH药物中的用途。提供的化合物I的晶型比现有技术具有一种或多种改进的性质，解决了现有技术存在的问题，对含化合物I药物的优化和开发具有重要价值。

Description

Resmetirom的晶型及其制备方法和用途 技术领域
本发明涉及晶体化学领域。具体而言，涉及Resmetirom的晶型及其制备方法和用途。
背景技术
杂合性家族性高胆固醇血症(HeFH)是脂质代谢疾病中最严重的一种，可导致各种危及生命的心血管疾病并发症。非酒精性脂肪性肝炎(NASH)是一种严重的肝脏疾病，伴随有炎症及肝细胞损伤的脂肪变性现象。Resmetirom作为一种甲状腺激素受体THR-β选择性激动剂，可通过降低低密度脂蛋白胆固醇、甘油三酯、肝脏脂肪水平，刺激NASH个体中肝脏线粒体生物合成，进而改善NASH和HeFH的症状。Resmetirom在NASH和HeFH的临床II期试验中取得了积极的成果。
Resmetirom的化学名称为2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧代-2,3,4,5-四氢-1,2,4-三嗪-6-甲腈(以下称为“化合物I”)，其结构式如下：
Figure PCTCN2021115205-appb-000001
晶体是化合物分子在微观结构中三维有序排列而形成晶格的固体。多晶型是指一种化合物存在多种晶体形式的现象。化合物可能以一种或多种晶型存在，但是无法具体预期其存在与特性。不同晶型的原料药有不同的理化性质，可能导致药物在体内有不同的溶出、吸收，进而在一定程度上影响药物的临床疗效。特别是一些难溶性口服固体或半固体制剂，晶型对产品性能至关重要。除此之外，晶型的理化性质对生产过程至关重要。因此，多晶型是药物研究和药物质量控制的重要内容。US9266861B2中公开了化合物I的水合物、无水晶型I、甲基异丁酮溶剂合物、二甲基乙酰胺溶剂合物。根据ICH对残留溶剂进行分类的规定，甲基异丁酮和二甲基乙酰胺均是二类溶剂，属于限制使用的重度毒类，不适合药用。US9266861B2公开化合物I的水合物纯度仅为96.4％(HPLC)，其较高的杂质含量会使药物外观性状产生变异，并影响药物的稳定性，增加毒副作用。
WO2020010068A1公开化合物I的钙盐、镁盐、钠盐、钾盐、乙醇胺盐等多种盐形态晶型。同时，其公开化合物I的27种游离态晶型，其中包含多种溶剂合物晶型(如甲醇溶剂合物、丙酮溶剂合物、四氢呋喃溶剂合物、甲基异丁基酮溶剂合物、乙腈溶剂合物、二甲基亚砜溶剂合物、二甲基乙酰胺溶剂合物)和多个脱溶剂合物晶型。根据WO2020010068A1公开的内容以及本申请发明人进行的实验研究可知，晶型A与US9266861B2公开的晶型I为同一晶型，脱溶剂合物晶型F的引湿性大，脱溶剂合物晶型S+T、晶型V、晶型W、晶型Z均为非单一晶型组成的混晶。
晶型I是已知的性质相对较好的化合物I固体形态，但是晶型I需由特定的起始物料制备，如甲基异丁酮溶剂合物、二甲基乙酰胺溶剂合物。本申请发明人重复US9266861B2公开的制备方法得到晶型I，对晶型I的性质进行表征，结果显示：晶型I的溶解度低，研磨稳定性差，研磨后大部分转变为无定形，可压性差，流动性极差。因此，本领域仍然需要开发一种溶解度高、物理化学稳定性好、安全无毒、理化性质好的化合物I的单一结晶形式，以用于含化合物I的药物开发。
本申请发明人对化合物I进行了大量实验研究试图得到更适合药用的晶型，进行了300多个实验，但得到的大部分均是化合物I溶剂合物，例如甲醇溶剂合物、丙酮溶剂合物、四氢呋喃溶剂合物、氯苯溶剂合物、甲苯溶剂合物、环己酮溶剂合物等。本申请发明人发现化合物I极易和溶剂结合形成溶剂合物，得到稳定的非溶剂合物的单一晶型非常困难。
本申请的发明人意外发现了本发明提供的化合物I晶型CSVI，其在溶解度，引湿性，提纯效果，稳定性，黏附性，可压性，流动性，体内外溶出，生物有效性等方面中的至少一方面存在优势，特别是溶解度大、物理化学稳定性好、机械稳定性好、引湿性低、流动性好、可压性好、黏附性低、制剂稳定性好，解决了现有技术存在的问题，对含化合物I的药物开发具有非常重要的意义。
发明内容
本发明提供化合物I的新晶型及其制备方法以及包含该新晶型的药物组合物。
根据本发明的目的，本发明提供化合物I的晶型CSVI(以下称作“晶型CSVI”)。
一方面，使用Cu-Kα辐射，所述晶型CSVI的X射线粉末衍射图在衍射角2θ值为9.6°±0.2°、10.1°±0.2°、18.9°±0.2°处有特征峰。
进一步地，使用Cu-Kα辐射，所述晶型CSVI的X射线粉末衍射图在衍射角2θ值为11.6°±0.2°、19.5°±0.2°、23.3°±0.2°中的1处、或2处、或3处有特征峰；优选地，所述晶型CSVI的X射线粉末衍射图在衍射角2θ为11.6°±0.2°、19.5°±0.2°、23.3°±0.2°中的3处有特征峰。
进一步地，使用Cu-Kα辐射，所述晶型CSVI的X射线粉末衍射图在衍射角2θ值为13.7°±0.2°、20.6°±0.2°、31.9°±0.2°中的1处、或2处、或3处有特征峰；优选地，所述晶型CSVI的X射线粉末衍射图在衍射角2θ为13.7°±0.2°、20.6°±0.2°、31.9°±0.2°中的3处有特征峰。
另一方面，使用Cu-Kα辐射，所述晶型CSVI的X射线粉末衍射图在衍射角2θ值为9.6°±0.2°、10.1°±0.2°、11.6°±0.2°、18.9°±0.2°、19.5°±0.2°、23.3°±0.2°、13.7°±0.2°、20.6°±0.2°、31.9°±0.2°、6.5°±0.2°、16.2°±0.2°、21.9°±0.2°、24.1°±0.2°、24.8°±0.2°、25.7°±0.2°、26.7°±0.2°、27.3°±0.2°、31.1°±0.2°中的至少3处有特征峰。
非限制性地，使用Cu-Kα辐射，晶型CSVI的X射线粉末衍射图基本如图1所示。
非限制性地，晶型CSVI的热重分析图基本如图2所示，其加热至250℃具有约0.2％的质量损失。
非限制性地，晶型CSVI在25℃/80％RH条件下引湿增重0.07％，属于无或几乎无引湿性，其DVS图基本如图3所示。
非限制性地，晶型CSVI为无水晶型。
另一方面，本发明还提供晶型CSVI的制备方法，其特征在于，所述制备方法包括：
(1)将化合物I在腈类或腈类和水的混合溶剂中悬浮搅拌，分离固体并干燥得到晶型CSVI；或
(2)将化合物I在腈类和水的混合溶剂或腈类和醇类的混合溶剂中溶解，过滤，将得到的滤液冷却，搅拌得到固体，分离并干燥得到晶型CSVI。
进一步地，方法(1)所述腈类优选乙腈，混合溶剂中乙腈和水的体积比优选95:5；方法(2)所述腈类优选乙腈，所述醇类优选异丙醇，混合溶剂中乙腈和水的体积比优选95:5，乙腈和异丙醇体积比优选1:1。
更进一步地，方法(1)所述搅拌温度优选-20℃-76℃，更优选-20℃-30℃；所述干燥温度优选10℃-70℃，更优选10℃-40℃。
更进一步地，方法(2)所述溶解温度优选40℃-76℃；所述冷却温度优选-20℃-5℃，更优选-20℃；所述干燥温度优选10℃-70℃，更优选10℃-40℃。
根据本发明的目的，本发明晶型CSVI用于制备化合物I其他晶型或盐的用途。
根据本发明的目的，本发明还提供一种药物组合物，所述药物组合物包含有效治疗量的晶型CSVI及药学上可接受的辅料。
进一步地，本发明提供的晶型CSVI在制备THR-β选择性激动剂药物制剂中的用途。
更进一步地，本发明提供的晶型CSVI在制备治疗NASH和HeFH药物制剂中的用途。
本发明提供的晶型CSVI具有以下优势：
(1)与现有技术相比，本发明提供的晶型CSVI具有更高的溶解度。特别是在SGF中，晶型CSVI的溶解度约为现有技术晶型I的2倍。
化合物I是水溶性差的药物。本发明提供的晶型CSVI有更高的溶解度，有利于提高药物在人体内的吸收，提高生物利用度；另外，更高的溶解度能够在保证药物疗效的同时，降低药品的剂量，从而降低药品的副作用并提高药品的安全性。
(2)与现有技术相比，本发明提供的晶型CSVI具有更低的引湿性。测试结果表明，现有技术晶型I的引湿增重约是本发明晶型CSVI的引湿增重的2倍。
一方面，高引湿性易引起原料药发生化学降解和晶型转变，从而直接影响原料药的物理化学稳定性。此外，引湿性高会降低原料药的流动性，从而影响原料药的加工工艺。
另一方面，引湿性高的药物在生产和保存过程中需要维持低的湿度，对生产提出了更高的要求，需要很高的成本。更重要的是，引湿性高容易造成药物中有效成分含量的变化，影响药物的质量。
(3)与现有技术相比，本发明提供的晶型CSVI具有更优的可压性。晶型CSVI好的可压性可以有效改善压片工艺中的硬度/脆碎度不合格、裂片等问题，使制剂工艺更为可靠，改善产品外观，提升产品质量和生产效率。
(4)与现有技术相比，本发明提供的晶型CSVI具有更低的黏附性。黏附性评价结果表明，现有技术晶型I的黏附量是晶型CSVI黏附量的5倍。更优的黏附性能有效减少原料药的团聚，能有效改善或者避免干法制粒和片剂压片等环节引起的黏轮、黏冲等现象，有利于原料的分散及与辅料的混合，提高物料混合时的混合均匀度，最终提高产品质量。
(5)本发明提供的晶型CSVI原料药和制剂均具有良好的物理化学稳定性。晶型CSVI原 料药在25℃/60％RH条件下开口和闭口放置，至少6个月晶型未发生变化，且化学纯度在99.7％以上，储存过程中纯度基本保持不变。晶型CSVI与辅料混合做成药物制剂后，在25℃/60％RH条件下放置，至少3个月晶型未发生变化，储存过程中纯度基本保持不变。说明晶型CSVI原料药和制剂在长期条件下具有较好的稳定性，有利于药物的储存。
同时，晶型CSVI原料药在40℃/75％RH条件下开口和闭口放置，至少6个月晶型未发生变化，且化学纯度在99.7％以上，储存过程中纯度基本保持不变。晶型CSVI与辅料混合做成药物制剂后，在40℃/75％RH条件下放置，至少3个月晶型未发生变化，储存过程中纯度基本保持不变。说明晶型CSVI原料药和制剂在加速条件下，具有较好的稳定性。原料药和制剂在加速条件下的稳定性对于药物至关重要。季节差异、不同地区气候差异和环境因素等带来的高温和高湿条件会影响原料药的储存、运输、生产。因此，原料药在加速条件下的稳定性对于药物至关重要。晶型CSVI原料药和制剂在苛刻的条件下具有更好的稳定性，有利于避免药物储存过程中因转晶或纯度下降对药物质量产生影响。
(6)本发明提供的晶型CSVI具有良好的机械稳定性。晶型CSVI原料药研磨后晶型未发生变化。制剂加工过程中常需要将原料药研磨粉碎，良好的物理稳定性能够降低制剂加工过程中原料药结晶度降低和转晶的风险。在不同压力下，晶型CSVI原料药均具有良好的物理稳定性，有利于在制剂压片工艺中保持晶型稳定。
原料药晶型良好的物理和化学稳定性可以确保药物在生产和存储的过程中不会发生转晶且基本没有杂质产生。晶型CSVI具有良好的物理化学稳定性，保证原料药和制剂质量一致可控，减少由于晶型改变或杂质产生引起的药物质量变化，生物利用度变化，和毒副作用。
附图说明
图1实施例1所得晶型CSVI的XRPD图
图2实施例1所得晶型CSVI的TGA图
图3实施例1所得晶型CSVI的DVS图
图4实施例1所得晶型CSVI在DVS前后的XRPD对比图(从上至下依次为：DVS前，DVS后)
图5实施例2所得晶型CSVI的XRPD图
图6晶型CSVI在不同条件放置前后XRPD对比图(从上至下依次为：放置前，在25℃/60％RH开口放置6个月，40℃/75RH开口放置6个月)
图7晶型CSVI在不同条件放置前后XRPD对比图(从上至下依次为：放置前，在25℃/60％RH闭口放置6个月，40℃/75RH闭口放置6个月)
图8晶型CSVI在不同压力条件下的XRPD对比图(从上至下依次为：14KN，7KN，3KN，压片前)
图9晶型CSVI制剂前后的XRPD对比图(从上至下依次为：空白片剂，制剂工艺后，晶型CSVI)
图10晶型CSVI制剂闭口放置前后的XRPD对比图(从上至下依次为：起始，25℃/60％RH放置3个月，40℃/75％RH放置3个月)
具体实施方式
结合以下实施例对本发明做详细说明，所述实施例详细描述本发明的晶型的制备和使用方法。对本领域技术人员显而易见的是，对于材料和方法两者的许多改变可在不脱离本发明范围的情况下实施。
本发明中所用到的缩写的解释如下：
XRPD：X射线粉末衍射
TGA：热重分析
DVS：动态水分吸附
1H NMR：液态核磁氢谱
HPLC：高效液相色谱
BCS：生物药剂学分类系统
RH：相对湿度
ICH：人用药品注册技术要求国际协调大会
采集数据所用的仪器及方法：
本发明所述的X射线粉末衍射图在Bruker D2 PHASER X射线粉末衍射仪上采集。本发明所述的X射线粉末衍射的方法参数如下：
X射线光源：Cu，Kα
Kα1
Figure PCTCN2021115205-appb-000002
1.5406；Kα2
Figure PCTCN2021115205-appb-000003
1.54439
Kα2/Kα1强度比例：0.50
电压：30仟伏特(kV)
电流：10毫安培(mA)
扫描范围(2θ)：自3.0至40.0度
本发明所述的热重分析(TGA)图在TA Q500上采集。本发明所述的热重分析(TGA)的方法参数如下：
扫描速率：10℃/min
保护气体：N 2
本发明所述动态水分吸附(DVS)图在由SMS公司(Surface Measurement Systems Ltd.)生产的Intrinsic动态水分吸附仪上采集。仪器控制软件是DVS-Intrinsic control software。所述的动态水分吸附仪的方法参数如下：
温度：25℃
载气，流速：N 2,200毫升/分钟
相对湿度范围：0％RH-95％RH
核磁共振氢谱数据( 1H NMR)采自于Bruker Avance II DMX 400M HZ核磁共振波谱仪。称量1-5mg样品，用0.5mL氘代二甲亚砜溶解，配成2-10mg/mL的溶液。
本发明所述有关物质检测的测试参数如表1所示：
表1
Figure PCTCN2021115205-appb-000004
Figure PCTCN2021115205-appb-000005
本发明所述溶解度的测试参数如表2所示：
表2
Figure PCTCN2021115205-appb-000006
Figure PCTCN2021115205-appb-000007
本发明中，所述“搅拌”，采用本领域的常规方法完成，例如磁力搅拌或机械搅拌，搅拌速度为50-1800转/分钟，其中，磁力搅拌速度优选300-900转/分钟，机械搅拌速度优选100-300转/分钟。
所述“分离”，采用本领域的常规方法完成，例如离心或过滤。“离心”的操作为：将欲分离的样品置于离心管中，以10000转/分的速率进行离心，至固体全部沉至离心管底部。
所述“干燥”，采用本领域的常规方法完成，例如真空干燥，鼓风干燥或自然晾干。干燥温度可以是室温或更高，优选室温到约80℃，或者到60℃，或者到40℃。干燥时间可以为2-48小时，或者过夜。干燥在通风橱、鼓风烘箱或真空烘箱里进行。
所述“特征峰”是指用于甄别晶体的有代表性的衍射峰，使用Cu-Kα辐射测试时，峰位置通常可以有±0.2°的误差。
本发明中，“晶体”或“晶型”可以用X射线粉末衍射表征。本领域技术人员能够理解，X射线粉末衍射图受仪器的条件、样品的准备和样品纯度的影响而有所改变。X射线粉末衍射图中衍射峰的相对强度也可能随着实验条件的变化而变化，所以衍射峰强度不能作为判定晶型的唯一或决定性因素。事实上，X射线粉末衍射图中衍射峰的相对强度与晶体的择优取向有关，本发明所示的衍射峰强度为说明性而非用于绝对比较。因而，本领域技术人员可以理解的是，本发明所保护晶型的X射线粉末衍射图不必和这里所指的实施例中的X射线粉末衍射图完全一致，任何具有和这些图谱中的特征峰相同或相似的X射线粉末衍射图的晶型均属于本发明的范畴之内。本领域技术人员能够将本发明所列的X射线粉末衍射图和一个未知晶型的X射线粉末衍射图相比较，以证实这两组图反映的是相同还是不同的晶型。
在一些实施方案中，本发明的晶型CSVI是纯的，基本没有混合任何其他晶型。本发明中，“基本没有”当用来指新晶型时指这个晶型含有少于20％(重量)的其他晶型，尤其指少于10％(重量)的其他晶型，更指少于5％(重量)的其他晶型，更指少于1％(重量)的其他晶型。
本发明中术语“约”，当用来指可测量的数值时，例如质量、时间、温度等，意味着可围绕具体数值有一定的浮动的范围，该范围可以为±10％、±5％、±1％、±0.5％、或±0.1％。
除非特殊说明，以下实施例均在室温条件下操作。所述“室温”不是特定的温度值，是指10-30℃温度范围。
根据本发明，作为原料的所述化合物I和/或其盐包括但不限于固体形式(结晶或无定形)、油状、液体形式和溶液。优选地，作为原料的化合物I和/或其盐为固体形式。
以下实施例中所使用的化合物I和/或其盐可以是现有技术公开的固体/晶型，例如根据WO2020010068A1专利所记载的方法制备获得。
具体实施方式
实施例1-2晶型CSVI的制备方法
实施例1
称取1.5801g化合物I固体于玻璃瓶中，向其中加入25mL乙腈，室温搅拌4天后，过滤分离，将得到的固体40℃鼓风干燥15.5h，得到本发明所述晶型CSVI。
晶型CSVI的XRPD图如图1所示，XRPD数据如表3所示。
晶型CSVI的TGA如图2所示，加热至250℃具有约0.2％的质量损失。
晶型CSVI的核磁数据为： 1H NMR(400MHz,DMSO-d6)δ13.28(s,1H),12.23(s,1H),7.79(s,2H),7.44(d,J＝0.8Hz,1H),3.04(dq,J＝13.5,6.8Hz,1H),1.20(d,J＝6.9Hz,6H)。
晶型CSVI的DVS图如图3所示，其在25℃/80％RH条件下引湿增重0.07％，属于无或几乎无引湿性。
晶型CSVI在DVS前后的XRPD对比图如图4所示，结果表明DVS前后晶型不变。
表3
衍射角2θ d值 强度％
6.49 13.62 2.06
9.57 9.25 65.84
10.11 8.75 100.00
11.58 7.65 7.89
12.77 6.93 0.88
13.68 6.48 3.39
13.98 6.33 0.91
14.75 6.00 2.41
16.19 5.48 4.32
17.64 5.03 1.13
18.10 4.90 2.23
18.94 4.68 10.63
19.50 4.55 19.67
19.81 4.48 4.75
20.33 4.37 1.63
20.61 4.31 7.02
21.62 4.11 2.74
21.86 4.07 2.96
22.66 3.92 4.89
22.91 3.88 2.66
23.29 3.82 8.60
23.72 3.75 1.44
24.14 3.69 0.98
24.80 3.59 3.03
24.98 3.57 4.96
25.69 3.47 1.87
26.12 3.41 3.40
26.75 3.33 4.17
27.31 3.27 2.57
27.57 3.24 1.94
28.01 3.19 1.85
29.19 3.06 1.72
29.79 3.00 2.09
31.13 2.87 1.30
31.90 2.81 4.91
32.68 2.74 1.98
33.48 2.68 1.87
33.77 2.65 1.24
34.37 2.61 1.29
35.45 2.53 1.92
36.44 2.47 1.70
38.27 2.35 1.43
39.14 2.30 3.36
实施例2
称取22.0mg化合物I固体于玻璃瓶中，向其中加入2.0mL乙腈和水混合溶剂(95:5,V:V)，在50℃溶解，过滤，将滤液置于-20℃搅拌4h析出固体，离心分离，得到的固体在25℃真空干燥2h，得到本发明所述晶型CSVI。
晶型CSVI的XRPD图如图5所示，XRPD数据如表4所示。
表4
衍射角2θ d值 强度％
6.48 13.65 9.15
9.55 9.26 51.51
10.09 8.76 100.00
11.56 7.65 10.22
13.00 6.81 1.45
13.67 6.48 6.38
13.97 6.34 1.56
14.71 6.02 2.42
16.18 5.48 9.37
17.61 5.04 0.98
18.11 4.90 1.81
18.93 4.69 22.10
19.49 4.56 18.39
19.82 4.48 2.83
20.61 4.31 4.81
21.61 4.11 3.08
21.84 4.07 7.91
22.64 3.93 4.23
22.88 3.89 3.26
23.27 3.82 12.36
24.97 3.57 3.66
25.62 3.48 1.81
26.11 3.41 3.28
26.73 3.34 3.74
27.28 3.27 2.52
27.59 3.23 2.25
27.96 3.19 5.37
29.20 3.06 1.70
29.76 3.00 1.82
31.13 2.87 3.79
31.91 2.81 5.06
32.69 2.74 2.33
33.43 2.68 3.01
34.36 2.61 2.57
35.41 2.53 1.64
36.43 2.47 1.33
38.18 2.36 1.33
39.15 2.30 2.37
实施例3晶型CSVI与现有技术晶型I的溶解度
进行药物溶解度测试以预测药物体内性能的时候，很重要的一点是尽可能的模拟体内条件。对口服药，用SGF(模拟胃液)可以模拟体内条件并预测进食的影响。在此类介质中测试的溶解度与人体环境中的溶解度更加接近。
取本发明晶型CSVI约15mg分散在2.0mL的SGF(模拟胃液)中，于37℃平衡1小时用高效液相色谱法测试溶液中样品的浓度(mg/mL)，结果如表5所示。
表5
Figure PCTCN2021115205-appb-000008
Figure PCTCN2021115205-appb-000009
备注：现有技术晶型I的溶解度数据引自WO2020010068A1。
结果表明，晶型CSVI在SGF中平衡1小时具有更高的溶解度，约是现有技术晶型I溶解度的2倍。
实施例4晶型CSVI与现有技术晶型I的引湿性
称取适量本发明晶型CSVI与现有技术晶型I，采用DVS仪测试其引湿性，在0-95％-0相对湿度下循环一次，记录每个湿度下的质量变化。
本发明晶型CSVI在DVS如图3所示，DVS测试前后的XRPD图如图4所示。
实验结果表明，晶型CSVI在25℃/80％RH条件下引湿性增重为0.07％，晶型I在25℃/80％RH条件下引湿性增重为0.13％。现有技术晶型I的引湿增重约是本申请晶型CSVI的2倍。
实施例5晶型CSVI的物理化学稳定性
称取适量本发明制备得到的晶型CSVI，分别放置在25℃/60％RH、40℃/75％RH条件下，采用HPLC和XRPD测定纯度与晶型。结果如表6所示，XRPD对比图如图6和图7所示。
表6
放置条件 放置时间 晶型 纯度
起始 —— CSVI 99.73％
25℃/60％RH开口 6个月 CSVI 99.73％
40℃/75％RH开口 6个月 CSVI 99.73％
25℃/60％RH闭口 6个月 CSVI 99.74％
40℃/75％RH闭口 6个月 CSVI 99.73％
结果表明，晶型CSVI在25℃/60％RH以及40℃/75％RH开口或闭口条件下均可以稳定至少6个月。由此可见，晶型CSVI在长期和加速条件下均可保持良好的稳定性。
实施例6晶型CSVI的机械稳定性
压力稳定性：
采用ENERPAC手动压片机进行压片，选择Φ6mm圆形平冲，加入约20mg晶型CSVI，在不同压力下压制成片，压片前后进行XRPD测试，测试结果如表7所示。压片前后的XRPD图如图8所示。
表7
Figure PCTCN2021115205-appb-000010
结果表明，在不同的压力下，晶型CSVI具有较好的稳定性。
研磨稳定性：
取适量本发明晶型CSVI置于研钵中，手动研磨5分钟。晶型CSVI研磨前后，晶型未发生变化。
实施例7晶型CSVI与现有技术晶型I的流动性
制剂工艺过程中，通常可采用可压性系数(Compressibility index)来评价粉体或颗粒的流动性，测定方法为将一定量的粉体轻轻装入量筒后测量振实前体积；采用轻敲法使粉体处于最紧状态，测量振实后体积；计算松密度ρ 0与振实密度ρ f；根据公式c＝(ρ f-ρ 0)/ρ f计算可压性系数。
可压性系数对粉体流动性的界定标准参考ICH Q4B附录13，详见表8。
表8
可压性系数(％) 流动性
≦10 极好
11-15 好
16-20 一般
21-25 可接受
26-31 差
32-37 很差
>38 极差
实验结果表明，现有技术晶型I的流动性极差，本申请晶型CSVI的流动性优于现有技术晶型I。
实施例8晶型CSVI与现有技术晶型I的可压性
采用ENERPAC手动压片机进行压片，压片时，选择Φ6mm圆形平冲，分别加入80mg现有技术晶型I和本发明晶型CSVI，采用10kN的压力压制成圆形片剂，室温放置24h，待完全弹性复原后，采用游标卡尺测量片剂的直径(D)和厚度(L)，采用片剂硬度测定仪测试其径向破碎力(硬度，H)。利用公式T＝2H/πDL计算粉体的抗张强度，结果如表9所示。
表9
晶型 厚度(mm) 直径(mm) 硬度(N) 抗张强度(MPa)
现有技术晶型I 2.12 6.06 7.4 0.37
晶型CSVI 2.05 6.06 13.4 0.69
结果表明，相比现有技术晶型I，晶型CSVI具有更优的可压性。
实施例9晶型CSVI与现有技术晶型I的黏附性
分别将约30mg晶型CSVI和现有技术晶型I加入到直径为8mm的圆形平冲中，采用ENERPAC手动压片机以10kN的压力进行压片，停留约半分钟，称量冲头吸附的粉末量，记录冲头压制过程中的最高黏附量和平均黏附量。具体的实验结果见表10。
表10
晶型 最高黏附量(mg) 平均黏附量(mg)
现有技术晶型I 0.30 0.25
晶型CSVI 0.10 0.05
实验结果表明，现有技术晶型I的平均黏附量是晶型CSVI的5倍，晶型CSVI的黏附性优于现有技术晶型I。
实施例10晶型CSVI的制剂制备
晶型CSVI的制剂处方和制剂工艺分别见表11和表12。晶型CSVI制剂前后的XRPD图如图9所示。结果表明，晶型CSVI在制剂前后，晶型保持不变。
表11
Figure PCTCN2021115205-appb-000011
表12
Figure PCTCN2021115205-appb-000012
实施例11晶型CSVI的制剂稳定性
将晶型CSVI制剂用HDPE瓶封装并加入1g干燥剂，于25℃/60％RH和40℃/75％RH的条件下放置并取样检测晶型及杂质，考察晶型CSVI的制剂稳定性，结果见表13所示。放置前后，晶型CSVI的制剂XRPD图如图10所示。
表13
放置条件 纯度变化(％) 晶型
起始制剂样品 N/A 晶型CSVI
25℃/60％RH闭口加1g干燥剂放置1个月 0.08％ 晶型CSVI
40℃/75％RH闭口加1g干燥剂放置1个月 0.05％ 晶型CSVI
25℃/60％RH闭口加1g干燥剂放置3个月 0.03％ 晶型CSVI
40℃/75％RH闭口加1g干燥剂放置3个月 0.03％ 晶型CSVI
结果表明，晶型CSVI制剂在25℃/60％RH和40℃/75％RH条件下可以至少保持3个月稳定，且纯度未发生明显变化。
上述实施例只为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰，都应涵盖在本发明的保护范围之内。

Claims (11)

  1. 化合物I
    Figure PCTCN2021115205-appb-100001
    的晶型CSVI，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为9.6°±0.2°、10.1°±0.2°、18.9°±0.2°处具有特征峰。
  2. 根据权利要求1所述的晶型CSVI，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为11.6°±0.2°、19.5°±0.2°、23.3°±0.2°中的1处或2处或3处具有特征峰。
  3. 根据权利要求1所述的晶型CSVI，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图在2θ值为13.7°±0.2°、20.6°±0.2°、31.9°±0.2°中的1处或2处或3处具有特征峰。
  4. 根据权利要求1所述的晶型CSVI，其特征在于，使用Cu-Kα辐射，其X射线粉末衍射图基本如图1所示。
  5. 一种权利要求1所述的晶型CSVI的制备方法，其特征在于，所述方法为：
    (1)将化合物I在腈类或腈类和水的混合溶剂中悬浮搅拌，分离固体并干燥得到晶型CSVI；或
    (2)将化合物I在腈类和水的混合溶剂或腈类和醇类的混合溶剂中溶解，过滤，将得到的滤液冷却，搅拌得到固体，分离并干燥得到晶型CSVI。
  6. 根据权利要求5所述的制备方法，其特征在于，方法(1)所述腈类为乙腈，所述混合溶剂中乙腈和水的体积比为95:5；方法(2)所述腈类为乙腈，所述醇类为异丙醇，所述混合溶剂中乙腈和水的体积比为95:5，乙腈和异丙醇体积比为1:1。
  7. 根据权利要求5所述的制备方法，其特征在于，方法(1)所述搅拌温度为-20℃-76℃，所述干燥温度为10℃-70℃；方法(2)所述溶解温度为40℃-76℃，所述冷却温度为-20℃-5℃，所述干燥温度为10℃-70℃。
  8. 根据权利要求7所述的制备方法，其特征在于，方法(1)所述搅拌温度为-20℃-30℃，所述干燥温度为10℃-40℃；方法(2)所述冷却温度为-20℃，所述干燥温度为10℃-40℃。
  9. 一种药物组合物，所述药物组合物包含有效治疗量的权利要求1中所述的晶型CSVI及药学上可接受的辅料。
  10. 权利要求1中所述的晶型CSVI在制备THR-β选择性激动剂药物中的用途。
  11. 权利要求1中所述的晶型CSVI在制备治疗NASH和HeFH药物中的用途。
PCT/CN2021/115205 2020-09-10 2021-08-30 Resmetirom的晶型及其制备方法和用途 WO2022052822A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP21865878.9A EP4286377A1 (en) 2020-09-10 2021-08-30 Crystal form of resmetirom, preparation method therefor, and use thereof
CN202180055080.9A CN116171275A (zh) 2020-09-10 2021-08-30 Resmetirom的晶型及其制备方法和用途
JP2023515709A JP2023541870A (ja) 2020-09-10 2021-08-30 レスメチロム（ｒｅｓｍｅｔｉｒｏｍ）の結晶形態、その調製方法、及びその使用について
US18/044,717 US20230416234A1 (en) 2020-09-10 2021-08-30 Crystal form of resmetirom, preparation method therefor, and use thereof
KR1020237011972A KR20230066408A (ko) 2020-09-10 2021-08-30 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도
AU2021341182A AU2021341182A1 (en) 2020-09-10 2021-08-30 Crystal form of resmetirom, preparation method therefor, and use thereof
CA3192243A CA3192243A1 (en) 2020-09-10 2021-08-30 Crystal form of resmetirom, preparation method therefor, and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010948981 2020-09-10
CN202010948981.8 2020-09-10

Publications (1)

Publication Number Publication Date
WO2022052822A1 true WO2022052822A1 (zh) 2022-03-17

Family

ID=80630255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/115205 WO2022052822A1 (zh) 2020-09-10 2021-08-30 Resmetirom的晶型及其制备方法和用途

Country Status (8)

Country Link
US (1) US20230416234A1 (zh)
EP (1) EP4286377A1 (zh)
JP (1) JP2023541870A (zh)
KR (1) KR20230066408A (zh)
CN (1) CN116171275A (zh)
AU (1) AU2021341182A1 (zh)
CA (1) CA3192243A1 (zh)
WO (1) WO2022052822A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022171200A1 (zh) * 2021-02-10 2022-08-18 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228135A (zh) * 2005-07-21 2008-07-23 霍夫曼-拉罗奇有限公司 作为甲状腺激素受体激动剂的哒嗪酮衍生物
US9266861B2 (en) 2012-09-17 2016-02-23 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
CN110167557A (zh) * 2016-10-18 2019-08-23 马德里加尔制药公司 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法
WO2020010068A1 (en) 2018-07-02 2020-01-09 Madrigal Pharmaceuticals, Inc. Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile
WO2020227549A1 (en) * 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228135A (zh) * 2005-07-21 2008-07-23 霍夫曼-拉罗奇有限公司 作为甲状腺激素受体激动剂的哒嗪酮衍生物
US9266861B2 (en) 2012-09-17 2016-02-23 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
CN105008335B (zh) * 2012-09-17 2018-12-21 马德里加尔制药公司 合成甲状腺激素类似物及其多形体的方法
CN110167557A (zh) * 2016-10-18 2019-08-23 马德里加尔制药公司 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法
WO2020010068A1 (en) 2018-07-02 2020-01-09 Madrigal Pharmaceuticals, Inc. Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile
WO2020227549A1 (en) * 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTHA J. KELLY, SHERRIE PIETRANICO-COLE, J. DOUGLAS LARIGAN, NANCY-ELLEN HAYNES, CHARLES H. REYNOLDS, NATHAN SCOTT, JOHN VERMEULE: "Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 10, 22 May 2014 (2014-05-22), US , pages 3912 - 3923, XP055436939, ISSN: 0022-2623, DOI: 10.1021/jm4019299 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022171200A1 (zh) * 2021-02-10 2022-08-18 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途

Also Published As

Publication number Publication date
JP2023541870A (ja) 2023-10-04
KR20230066408A (ko) 2023-05-15
CA3192243A1 (en) 2022-03-17
US20230416234A1 (en) 2023-12-28
AU2021341182A1 (en) 2023-04-27
EP4286377A1 (en) 2023-12-06
CN116171275A8 (zh) 2024-05-17
CN116171275A (zh) 2023-05-26
AU2021341182A9 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
CN113242855B (zh) 他发米帝司的晶型及其制备方法和用途
US11066384B2 (en) Crystalline forms of ARN-509, preparation method and use thereof
WO2020177645A1 (zh) 一种Upadacitinib的晶型及其制备方法和用途
WO2021129467A1 (zh) 一种bms-986165晶型及其制备方法和用途
WO2022078269A1 (zh) Avacopan的晶型及其制备方法和用途
US20220372021A1 (en) Resmetirom crystal, preparation method for same, and uses thereof
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
WO2021063367A1 (zh) 一种Resmetirom晶型及其制备方法和用途
WO2022052822A1 (zh) Resmetirom的晶型及其制备方法和用途
WO2021143498A1 (zh) 一种Deucravacitinib的晶型及其制备方法和用途
WO2021143430A1 (zh) 一种bms-986165盐酸盐晶型及其制备方法和用途
WO2023208133A1 (zh) 布拉美森盐酸盐的晶型及其制备方法和用途
EP3733666B1 (en) Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
WO2022036782A1 (zh) 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
WO2021232619A1 (zh) 一种他发米帝司游离酸的晶型及其制备方法和用途
WO2023143321A1 (zh) 他伐帕敦的晶型及其制备方法和用途
WO2023227029A1 (zh) 艾拉司群二盐酸盐的晶型及其制备方法和用途
CN114344301B (zh) 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型
US20220267326A1 (en) Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
WO2020151672A1 (zh) 一种达格列净晶型及其制备方法和用途
WO2022021684A1 (zh) 一种bms-986165盐酸盐晶型csv及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21865878

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023515709

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3192243

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: AU2021341182

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20237011972

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2021865878

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021341182

Country of ref document: AU

Date of ref document: 20210830

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021865878

Country of ref document: EP

Effective date: 20230411

122 Ep: pct application non-entry in european phase

Ref document number: 21865878

Country of ref document: EP

Kind code of ref document: A1